Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06001372 | Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers(TREK) | terminated | Early Phase 1 | 2 | University of UtahOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06887673 | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds | not yet recruiting | Early Phase 1 | 56 | University of South FloridaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06853769 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer(LARC-nCR01) | active not recruiting | Early Phase 1 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06276686 | Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer | recruiting | Early Phase 1 | 30 | University of HullOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT01821612 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer | completed | Early Phase 1 | 23 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03153410 | Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | completed | Early Phase 1 | 11 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06652243 | Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma(SN301A) | recruiting | Early Phase 1 | 12 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06690476 | Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma | recruiting | Early Phase 1 | 74 | Peking UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06646783 | Phase IIT Trial of SNA014 | not yet recruiting | Early Phase 1 | 28 | SmartNuclide BiopharmaINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04310540 | PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer | completed | Early Phase 1 | 42 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03970252 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | completed | Early Phase 1 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06525714 | Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 302 | The First Hospital of Jilin UniversityOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT03492164 | In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer | terminated | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06446050 | Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer | recruiting | Early Phase 1 | 30 | Shanghai East HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06432075 | Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | May 29, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT05359146 | Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)(Beta plus) | unknown | Early Phase 1 | 16 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06347198 | Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | unknown | Early Phase 1 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06326736 | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | recruiting | Early Phase 1 | 12 | Jinling Hospital, ChinaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03519308 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | terminated | Early Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06224738 | Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases | unknown | Early Phase 1 | 9 | First People's Hospital of HangzhouOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | not yet recruiting | Early Phase 1 | 6 | Zhang Xiaofeng,MDOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT06173726 | Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer | not yet recruiting | Early Phase 1 | 6 | BioSyngen Pte LtdINDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06152757 | BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors | recruiting | Early Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04977882 | Abdominal Drainage, Postoperative Antibiotico-prophylaxis and CME With D3 Lyphadenectomy Effect on Gastrointestinal Function in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis for Right Colon Cancer | completed | Early Phase 1 | 36 | University of Rome Tor VergataOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03395847 | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | completed | Early Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06104241 | BGT007 Cells for the Treatment of Refractory Digestive System Tumors | recruiting | Early Phase 1 | 14 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06098898 | Safety and Efficacy of NK510 to Treat Gastric Cancer | unknown | Early Phase 1 | 9 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06054984 | TCR-T Cells in the Treatment of Advanced Pancreatic Cancer(GB3010-02) | unknown | Early Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT02683824 | Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers | completed | Early Phase 1 | 21 | Stanford UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05648955 | Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment(ALLIES) | unknown | Early Phase 1 | 118 | Nutricia ResearchINDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05888675 | Clinical Study of Weifuchun Treatment on Gastric Cancer | completed | Early Phase 1 | 72 | ShuGuang HospitalOTHER | 0 | Jul 25, 2023 | clinicaltrials |
| NCT05937919 | 68Ga-PMD22 PET/CT Examination Targeting CLDN18.2 | unknown | Early Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT05908838 | Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer | completed | Early Phase 1 | 146 | ShuGuang HospitalOTHER | 0 | Jun 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 16, 2025source: clinicaltrials